Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Length of Second Stage Clear all
Completed Not applicable Interventional

A Mind-body Intervention to Improve Body and/or Self Image

NCT02531997
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions
Hypnotic Relaxation Therapy, Progressive Muscle Relaxation
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 9, 2026, 1:58 AM EDT
Terminated Phase 2 Interventional

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

NCT05588609
View directory record Official record
Conditions
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
Interventions
Afatinib Oral Tablet, Enzalutamide Pill, Abiraterone acetate tablets, MCLA-128
Drug · Biological
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Whittier, California • Lake Mary, Florida • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Completed No phase listed Observational

Germline Mutations in Patients With Head and Neck Cancer and a Family History of Cancer

NCT00482872
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, flow cytometry, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

NCT01954745
View directory record Official record
Conditions
Bile Duct Cancer, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct
Interventions
Cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Sep 9, 2026, 1:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

NCT06999733
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
KB801, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Irvine, California • Pasadena, California • Carmel, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Randomized Control Trial of Second Stage of Labor

NCT02101515
View directory record Official record
Conditions
Labor Complications
Interventions
Length of Second Stage
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 9, 2026, 1:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

DNA Variations in the Gene in Young Patients With Wilms' Tumor

NCT00088803
View directory record Official record
Conditions
Kidney Cancer
Interventions
molecular genetic technique, polymerase chain reaction, polymorphism analysis
Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
471 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
205
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 9, 2026, 1:58 AM EDT
Terminated No phase listed Observational

Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

NCT00991991
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
gene expression analysis, polymerase chain reaction, polymorphism analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, medical chart review
Genetic · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 3 Interventional

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

NCT04450693
View directory record Official record
Conditions
Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Interventions
TTAX01, Standard care
Biological · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
16
States / cities
Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

NCT00611351
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Secondary Myelofibrosis
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, mycophenolate mofetil, tacrolimus, polymerase chain reaction, polymorphism analysis, flow cytometry, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Genetic + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional

DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements

NCT00550563
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cholecalciferol, polymerase chain reaction, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy, immunoscintigraphy
Dietary Supplement · Genetic · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Harnessing Placebo Effects in Methadone Treatment

NCT02941809
View directory record Official record
Conditions
Opioid-use Disorder, Opioid-Related Disorders
Interventions
Open-Label Placebo (OLP)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 9, 2026, 1:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA

NCT03887481
View directory record Official record
Conditions
Logopenic Progressive Aphasia, Primary Progressive Aphasia
Interventions
High-definition active tDCS (HD-tDCS) + "Repeat After Me" (RAM) Treatment, Sham + "Repeat After Me" (RAM) Treatment
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 9, 2026, 1:58 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

NCT04213261
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
2 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

NCT01453595
View directory record Official record
Conditions
Renal Cancer
Interventions
BEZ235
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 9, 2026, 1:58 AM EDT
Active, not recruiting Phase 1 Interventional

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

NCT03006172
View directory record Official record
Conditions
Breast Cancer, Solid Tumor
Interventions
Inavolisib, Fulvestrant, Letrozole, Palbociclib, Metformin, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

NCT01476410
View directory record Official record
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
Interventions
brentuximab vedotin, doxorubicin hydrochloride, vinblastine, dacarbazine, quality-of-life assessment, DNA analysis, RNA analysis, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis, immunohistochemistry staining method, polymorphism analysis
Drug · Procedure · Genetic + 2 more
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
7
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

NCT00005578
View directory record Official record
Conditions
Cardiac Toxicity, Lymphoma
Interventions
bleomycin sulfate, filgrastim, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 9, 2026, 1:58 AM EDT
Active, not recruiting Phase 1 Interventional

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

NCT02715284
View directory record Official record
Conditions
Neoplasms
Interventions
Dostarlimab
Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
48
States / cities
Birmingham, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Psychoeducational Videos and Digital Assessments for BPD

NCT05358925
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Psychoeducational Videos, Neuropsychological Feedback, Non-BPD-related Educational Videos
Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT03425643
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Placebo, Cisplatin, Gemcitabine, Pemetrexed
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
51
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional

A Comparison of mNT-BBAVF and BCAVF in Hemodialysis Patients

NCT02519933
View directory record Official record
Conditions
Vascular Fistula
Interventions
mNT-BBAVF, BCAVF
Procedure
Lead sponsor
Shanghai 10th People's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Exploratory Evaluation of [11C]-NOP46

NCT03705819
View directory record Official record
Conditions
Chronic Pain
Interventions
[11C]-NOP46, PET/CT scan
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

NCT00047320
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Childhood Germ Cell Tumor
Interventions
carboplatin, etoposide, ifosfamide, thiotepa, adjuvant therapy, conventional surgery, neoadjuvant therapy, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 24 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 9, 2026, 1:58 AM EDT